vincing data regarding the impact of protease inhibitors are the recent report from the Centers for Disease Control and Prevention that deaths from AIDS fell 23% in 1996 compared with the previous year. an effect seen in virtually all risk groups and in all regions of the country. 7 These salutary developments notwithstanding, in 1995 (the most recent year for which statistics have been released) HIV infection was the seventh leading cause of death in the United States, ahead of pneumonia and in fluenza, diabetes, suicide, homicide, and chronic liver disease. s It is the number one cause of death for Americans between the ages of 25 and 44. s In our enthusiasm to im plement new therapies, we must not forget the heavy burden of mortality that HIV will continue to visit on our soci ety. Two articles in this issue of JGIM address important issues in end-of-life care for persons with HIV. Singer et al. describe the development and testing of an HIV specific advance directive document. ' -~ They ran domized 203 persons with HIV infection to the Center for Btoethics Living Will (a generic advance directive docu ment), or the HIV Living Will (an HIV specific document), or both, Of the 101 participmlts who received both. most preferred the HIV specific document (77.2% vs 22.8%, p < .001). They also used a rating tool called the Advance Directive Assessment Questionnaire (ADAQ) to compare the two instruments. The mean ADAQ score was slightly higher for the condition specific document (68.5% vs 66.2%, p ,051). It is unlikely that this is a clinically important difference. Although Singer et al. do not demon 784 strate that having an HIV-specific advance directive document changed the care that these patients got, advanced planning must be tailored to the needs and wishes ofindi vidual patients, Any improvement that makes advance directives more relevant to patients" individual circum stances is a step in the right direction.
Aspects of the data that Singer et al. present, however, highlight some of the problems than can be associated with advance directives. Figures 1 and 2 in their article show that patients generally preferred less aggressive treatments if their illness was more advanced. Within specific illness sce narios, however, there was relatively little variation in pa tients" preferences for very different therapies. In most cases there were differences of roughly 5 to 15 points (on a 100 point scale) between preferences for cardiopulmonary resus citation (CPR) mid preferences for mKibiotics or a trmlsfusion. Is it possible that 1~25% of patients with a mild stroke or mild dementia really would not choose antibiotics for a treatable pneumonia or a trmlsfusion ff it would reduce symptoms of fatigue and breathlessness? I think not. It is more likely that patients have a general feeling about what they might want in these settings, but need help assessing the risks and benefits of these treatments in specific clinical scenarios. The limitations of advance directives have been thoroughly discussed elsewhere, ln,u Although advance directives may help get the conversation started, they are not intended to be a substitute for dialogue between physicians and patients about end-of-life care.
Talk about death is difficult for both physicians and patients, and in such discussions doctors and patients are usually not on the same page, 1~ 1, This discordance is not related in a simple way to factors such as how long doctors and patients have known each other, s~ Most clini cal interventions aimed at changing end-of-life care have failed to do so. ~1 In the SUPPORT study, the largest such effort, an intensive intervention directed at both physi cimls mid patients included timely provision of prognostic information by a trained nurse. This effort, however, failed to change the frequency of discussions about pre5 erences for CPR. physicians' knowledge of patients' CPR preferences, the use of intensive care, the use of mechan ical ventilation, or levels of pain reported by patients, s: A1 though the SUPPORT study did not include patients with HIV infection, there is every reason to believe that its con clusions would be generalizable to them. In this context the study by Curtis and Patrick, which also is described in this issue, is timely and relevant. :3 They conducted focus groups with 47 AIDS patients and 19 physicians who were experienced in AIDS care to ex plore both barriers and facilitators of discussions about end-of-life care, Some of their findings are not surprising: both physicians and patients expressed discomfort dis cussing death: each party waited for the other to initiate such discussions: physicians reported that time pressures during appointments were a barrier: physicians did not want to undermine patients" hope.
Other findings, however, are new and revealing. Both physicians and patients in Curtis and Patrick's study ex pressed the feeling that discussion of death can actually cause harm or death, Both physicimls mid patients also said that end oSlife discussions were sometimes avoided to protect physicians. Regarding advance directives, some patients felt that completing ml advance directive made further discussion about end o~life care unnecessary. Others whose treatment preferences were in flLkx didn't want their preferences "set in stone." One concerning finding was the report of patients that they perceived discrimination by the medical system against nonwhites, gays, drug users, and the poor. Physicimls perceived end-of-life discussions as not only time consuming but also complex and requi~ ing considerable energy and preparation. Physicians also reported that sometimes they were not ready for the patient to die.
This qualitative work of Curtis and Patrick reminds us to use research methods that are appropriate for the state of research in the field and the nature of the subject being examined, Quantitative work on ethical questions. which has expmlded greatly in the last ten years, has had some tremendous successes, but also some notable fall ures, Patients" responses to the experience of dying are complex, varied, and unpredictable, and our research methods should have the capacity to capture the richness and diversity of individuals" experiences at the end of life, Qualitative work such as that reported here by Curtis and Patrick can advance the field by deepening our unde~ standing of these phenomena, generating new and relevant hypotheses to be tested using quantitative methods. and ensuring that future interventions are informed by the specific barriers and facilitators to discussions of endof-life care identified by patients, These research findings should inform our clinical care, As clinicians we may find it useful to approach endof-life discussions in a less directed and more exploratory way. We will continue to feel time pressures. One could spend this limited time helping patients think through whether they might want a trmlsfusion or antibiotics should they develop a mild dementia or some other condi tion interfering with their participation in decision making. This approach is what some have called structured deliberation. ~ However, we might learn more about pa tients' preferences if we were to think about end oSlife discussions more as an ongoing dialogue, and less as a destination to be arrived at and documented in the chart. It is certainly true that physicimls need to work harder at helping patients think through end oflife issues. But some patients will fiercely resist our best efforts to talk about their death, simply cannot make decisions about what they want, or prefer to receive treatments that in volve significant burdens of suffering mid are not likely to extend life, ~,~ For these patients and others who do not "go gentle into that good night," dialogue must continue. We must travel with our patients through the final stages of their Journey. being sensitive to their individualized desires and designs. In many ways this Journey is the es sence of doctoring, a special privilege that we enjoy and should exploit more. 
